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Abstract: Cysteine-reactive small molecules are used as
chemical probes of biological systems and as medicines.
Identifying high-quality covalent ligands requires comprehen-
sive kinetic analysis to distinguish selective binders from pan-
reactive compounds. Quantitative irreversible tethering (qIT),
a general method for screening cysteine-reactive small mole-
cules based upon the maximization of kinetic selectivity, is
described. This method was applied prospectively to discover
covalent fragments that target the clinically important cell cycle
regulator Cdk2. Crystal structures of the inhibitor complexes
validate the approach and guide further optimization. The
power of this technique is highlighted by the identification of
a Cdk2-selective allosteric (type IV) kinase inhibitor whose
novel mode-of-action could be exploited therapeutically.
Small molecules that bind proteins selectively serve both as
tools to understand protein function and as therapeutics.
Although high-throughput screening has generated ligands
against many clinical targets, a large subset appears undrug-
gable as they lack deep hydrophobic pockets.[1] Fragment-
based ligand discovery (FBLD) is a complementary technique
that is able to generate ligands against many difficult-to-target
proteins.[2] Early strategies focused on non-covalent frag-
ments; however, recently FBLD has begun to incorporate
electrophilic molecules.[3–11] These fragments form covalent
bonds with nucleophilic amino acids on target proteins and
consist of a specificity-determining element and a reactive
warhead. Irreversible covalent modification proceeds under
kinetic control and when developing irreversible inhibitors,
warhead reactivity must be minimized and only become
significant upon target-engagement by the specificity ele-
ment. Acrylamides, which modify cysteine residues, have
recently become the most clinically successful covalent war-
head.[12]
Screening irreversible cysteine-reactive molecules by
comparing their rates of reaction with a target protein alone
is highly problematic as intrinsic electrophilic reactivity can
vary dramatically, even for fragments bearing identical war-
heads.[13] Therefore, to rank covalent inhibitors by affinity,
each moleculeQs inherent reactivity must be considered.
Unfortunately, it is difficult to predict electrophile–thiol
reactivity trends, such that either computationally expensive
QM/DFT calculations must be implemented or low-through-
put experimental techniques performed (for example, NMR
or LCMS).[14] Glutathione (GSH) is widely used for such
experiments, but the extent to which it models proteinaceous
cysteine reactivity, which is subject to the local protein
environment, is unknown. Furthermore, aerobic oxidation of
small molecule-derived thiols makes determination of kinet-
ics challenging.[15] Therefore, there is an urgent need for
methods to screen covalent fragments that relate protein
reactivity to intrinsic fragment electrophilicity.
To measure the kinetics of electrophile-thiol conjugation
we developed quantitative irreversible tethering (qIT),
a technique which employs fluorogenic thiol quantification
(FTQ) in a high-throughput thiol consumption assay (Fig-
ure 1a). A wide range of FTQ probes have previously been
applied in biochemical assays with great success and here we
identified 7-diethylamino-3-(4’-maleimidylphenyl)-4-methyl-
coumarin (CPM) as an ideal choice because of its impressive
fluorogenic amplitude, stability in reaction with both small
molecule- and protein-derived thiols and its widespread
availability.[16–20] However, using glutathione as a model
thiol, aerobic thiol oxidation prevented accurate thiol quan-
tification. Employment of soluble disulfide reducing agents
was unsuccessful as they react fluorogenically with FTQ
probes (Supporting Information, Figure S1) and operation
under anaerobic conditions proved impractical. We solved
this problem using an immobilized reducing agent (TCEP-
agarose, 2%w/v), allowing facile separation by centrifugation
before conducting the FTQ step (Figure 1b).
We constructed a 138-member electrophilic fragment
library, predominantly comprising acrylamide warheads but
also containing other electrophiles such as chloroacetamides,
epoxides and SNAr substrates, where each compound was
designed to be largely rule-of-three[21] compliant and possess
a unique Bemis–Murcko[22] framework (Supporting Informa-
tion, Figure S2). Electrophiles were individually reacted with
glutathione under pseudo-first-order conditions in the pres-
ence of TCEP-agarose. At eight timepoints over 126 hours, an
aliquot of each reaction was quenched into excess CPM.
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Fluorescence measurements were normalized against
a DMSO control and exponential regressions used to
determine rate constants. Under these conditions the kinetics
could be accurately modeled for reactions with half-lives (t1/2)
between 1 and 500 hours (mean R2= 0.79) which accounted
for 90% of the library (average half-life= 132 hours), while
the optimum half-life was between 1 and 200 hours (mean
R2= 0.87) (Figures 1c and d).
Next we tested whether qIT could also screen electro-
philic fragments against proteins. We chose to target Cdk2,
which is a clinically important protein in oncology, the activity
of which is important for driving cell replication and is
dependent upon association with a cyclin protein.[23]Although
Cdk2 possesses three cysteine residues, numerous Cdk2
crystal structures show that only one (C177) is surface-
exposed. Indeed, intact protein mass spectrometry showed
Cdk2 to be mono-modified by CPM while Cdk2(C177A)
remained unlabeled (Supporting Information, Figure S3).
Significantly, qIT was successful in determining the kinetics
of the electrophilic fragment library in reaction with C177 on
Cdk2, demonstrating its capability in quantifying reaction
kinetics for both small molecule- and protein derived-thiols in
high-throughput (Supporting Information, Table S1).
We then characterized the assayQs statistical robustness by
determining Z’ factors, where for application to high-
throughput screening Z’> 0.5, 0.6 or 0.7 is generally consid-
ered sufficient, good, or excellent, respectively.[24] Assays
against glutathione and Cdk2(WT) were compared to gluta-
mate and Cdk2(C177A) as negative controls. Since qIT relies
on consistent time-dependent measurements, Z’ factors were
determined at several time points after assay initiation,
revealing good-to-excellent (0.63<Z’< 0.74) performance
in all cases (Figure 2; Supporting Information, Figure S4).
The use of glutathione as a control thiol for investigating
proteinaceous cysteine reactivity has recently been brought
into question.[5] To explore this, we screened our compound
library against a set of seven Cdk2(C177A) mutants, each
containing a single surface-exposed cysteine residue in differ-
ent settings, including a cryptic hydrophobic binding pocket[25]
(H71C), a protein-protein interaction interface (S276C) as
Figure 1. Quantitative irreversible tethering (qIT). a) Assay overview. The target thiol (5 mm) is reacted with electrophilic fragments (0.5 mm)
under pseudo-first-order conditions in the presence of TCEP-agarose (2% w/v). Reaction progress is followed by discrete measurements of
residual target thiol concentration using the fluorogenic probe CPM and rate constants are derived from exponential regression analysis. b) TCEP-
agarose prevents aerobic thiol oxidation. Glutathione solutions were stored :TCEP-agarose (2% w/v). Agarose-beads were separated by
centrifugation prior to fluorogenic thiol quantification with CPM after one hour or five days. c) Performance of qIT in determining rate constants
for library members in reaction with glutathione is reflected by the coefficient of determination (R2) for each exponential regression. d) Accuracy
of kinetic modeling as a function of reaction half-life (t1/2). Optimum assay performance is achieved when 1> t1/2>200 hours.
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well as basic (T182C) and acidic (N272C) local environments.
Accordingly, we generated a matrix of 1080 rate constants and
thence determined the average reactivity of each fragment
and each target thiol (Supporting Information, Table S1).
Next we performed correlation analysis, comparing fragment
reactivity with glutathione (kGSH) against average fragment
reactivity across the seven proteins (k¯protein). Interestingly, we
found strong correlation between the two data sets (Fig-
ure 3a), implying that glutathione can function as an effective
control for intrinsic reactivity and suggesting that rate
enhancement factor (REF= kprotein/kGSH) could be used to
rank hit ligands. To achieve a false-discovery rate of less than
2.5%, we defined rate accelerated and retarded fragments
being those with a REF > 3 and < 0.3, respectively (Support-
ing Information, Figure S5).
Cys177 on Cdk2(WT) is positioned adjacent to the cyclin-
binding interface, and we next investigated whether covalent
modification of this site could affect the holoenzymeQs
activity. Among the fragments that showed accelerated
reactivity with Cdk2(WT), acrylamide 1 (REF= 5.0) was
further investigated because of its impressive proteinaceous
selectivity profile (Figures 3b,c; Supporting Information,
Figure S6). Intact protein mass spectrometry confirmed that
acrylamide 1mono-modifies Cdk2(WT), even in the presence
of millimolar glutathione, while Cdk2(C177A) was unaffected
(Supporting Information, Figure S7). Interestingly, Cdk2-
(WT) completely modified with acrylamide 1 exhibited
about 83% inhibition of kinase activity (Figure 4). A series
of analogues, synthesized to probe the mechanism of inhib-
ition, revealed that the aromatic ring is crucial to binding
specificity while functionalization of the aromatic ring was
tolerated for effective labeling and inhibition (Supporting
Information, Figures S8 and S9). Interestingly, although
substitution of the tert-butyl carbamate for a methyl carba-
mate (acrylamide 2) resulted in a similar labeling profile
(REF= 2.6, kGSH= 0.089 h
@1, kCdk2(WT)= 0.233 h
@1), no signifi-
cant inhibition was observed.
Crystallization of 1-Cdk2(WT) showed that the acrylam-
ide had labeled Cys177 with the ligand bound into a shallow
pocket adjacent to the cyclin-binding interface, interacting
with Trp227 and Met233 (Figure 5a). Based on comparison
with the structure of Cdk2-cyclin A2 (PDB: 1FIN), acrylam-
ide 1 points away from the protein–protein interface and so
direct hindrance of cyclin binding is unlikely to be the
mechanism of Cdk2 inhibition. Although 1-Cdk2(WT)
showed only minor structural deviations from Cdk2(WT) in
the region surrounding the ligand, significant distortion was
observed around the aC-helix (Supporting Information,
Figure S11). The aC-helix is essential for proper formation
of the active Cdk2-cyclin complex and its displacement is
implicit in allosteric modulation of various kinases.[26, 27]
To model how acrylamide 1 was affecting enzymatically
relevant changes to the structure and dynamics of Cdk2,
molecular dynamics (MD) simulations were performed. In
a 50 ns MD run, 1-Cdk2(WT) showed increased flexibility
compared to Cdk2(WT) across the entire structure, with the
exception of the aC-helix, suggesting a general destabilization
of the protein which is supported by an experimentally
Figure 2. Z’ factor analysis for qIT. Positives=Cdk2(WT) and GSH;
negatives=Cdk2(C177A) and glutamate (n=72).
Figure 3. a) Correlation analysis comparing fragment reactivity with glutathione (kGSH) to average fragment reactivity across seven Cdk2 mutants
(k¯protein). b) Distribution of rate enhancement factors for the covalent fragment library screened against Cdk2(WT). c) DMSO-Normalized
fluorescence data from qIT assay for acrylamide 1 (0.5 mm) in reaction with Cdk2(WT) or glutathione (5 mm) (n=2).
Figure 4. Kinase activity of 1-Cdk2(WT) (16.8:3.1%) and 2-Cdk2(WT)
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observed drop in melting temperature (DTm=@3.4 8C) (Fig-
ures 5b and c).
Interestingly, while crystallization of 2-Cdk2(WT)
revealed that acrylamides 1 and 2 adopt similar binding
conformations, the representative structure from the MD
trajectory of 1-Cdk2(WT) is closer to Cdk2(WT) at the aC-
helix, with only a modest change in global flexibility
(Supporting Information, Figure S12). Indeed, 2-Cdk2(WT)
is only moderately destabilized (DTm=@1.7 8C) relative to
Cdk2(WT), which correlates with its weak inhibition.
Although several Cdk2-targeting drugs have failed in
clinical trials as chemotherapeutics, these ATP-competitive
inhibitors had only moderate selectivity for Cdk2.[28] Indeed,
owing to the similarity of their ATP-binding sites, Cdk1 has
proved especially hard to eliminate as an off-target and the
resulting Cdk1-dependent toxicity narrows the therapeutic
window (Figure 6b). Conducting a kinome-wide sequence
alignment revealed that the pocket surrounding Cys177
(Cdk2 residues 169–298) is present within much of the
CMGC kinase group, with Cdks showing the closest sim-
ilarity. However, it is noteworthy that only Cdk2 has a cysteine
at the position equivalent to 177 and we therefore anticipated
that the strategy of Cys177 modification would enable
unprecedented specificity for Cdk2 inhibition (Figure 6a).[29]
Indeed, acrylamide 1 failed to inhibit Cdk1-cyclin A2 in vitro
after prolonged exposure (24 hours; Figure 6c).
To evaluate whether this in vitro activity would translate
into in-cell target engagement, acrylamide 3 (REFCdk2(WT)=
5.6, kGSH= 0.033 h
@1, kCdk2(WT)= 0.185 h
@1) was synthesized as
a target engagement probe, containing an alkyne handle for
bio-orthogonal ligation. HeLa cells were treated with probe 3
and protein lysates subjected to copper(I) catalyzed azide–
alkyne cycloaddition (CuAAC)[30] to affect biotin conjuga-
tion. After pull-down with Neutravidin beads, western blot
analysis revealed a concentration-dependent enrichment of
Cdk2, while Cdk1 was not isolated (Figure 7). These data
demonstrate that, by virtue of targeting a unique cysteine,
these cell-permeable acrylamides provide a starting point for
a novel class of Cdk2-selective probes.
In conclusion, we have established a platform for screen-
ing electrophilic fragments with heterogeneous reactivity by
virtue of parallel kinetic analysis of target and control thiols.
Using this approach, we were able to rapidly identify and
validate hit-fragments against a shallow pocket. Moreover, we
have shown how covalent modification of a unique cysteine
residue can enable allosteric modulation of Cdk2 activity with
unprecedented selectivity. The assay is directed to a prede-
fined site on the target protein and is independent of the
Figure 5. a) Crystal structure of 1-Cdk2(WT) (resolution: 1.83 b, PDB ID: 5OSJ). 2Fo@Fc Electron density map (blue) is contoured at 1s around
C177 (yellow) and the ligand (green). b) Molecular dynamics simulations (50 ns) of 1-Cdk2(WT) and 2-Cdk2(WT) (resolution: 1.72 b, PDB ID:
5OO0). Atomic flexibility (root mean square fluctuations) was compared to a similar simulation for Cdk2(WT) (ligands in green, flexibility:
red= increase; blue=decrease and grey=unperturbed). c) Tm were determined by TdCD (n=3; error bars=SD). **, *** and **** denote
P<0.01, 0.001 and 0.0001 respectively in two-tailed T-test).
Figure 6. a) Sequence alignment of Cdk family. Cys177 is highlighted
in yellow. b) Published selectivity profiles of selected Cdk2 inhibitors.[29]
c) Active Cdk1/Cdk2:cyclin A2 was incubated with acrylamides 1 and 2
(0.5 mm) for 24 hours and then their in vitro kinase activity was
measured (n=3).
Figure 7. HeLa cells were treated with 3 for 6 hours. After tagging with
biotin-azide, Neutavidin pulldown was performed. Western blot analy-
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protein function, making it ideal to screen for inhibitors of
protein–protein interactions, for example. We envisage that
this simple and cost effective approach to target-directed
covalent ligand discovery will accelerate the development of
new chemical probes and expand the size of the druggable
proteome.
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